Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Plans to Submit 4 Bills to This Year’s Ordinary Diet Session
January 16, 2024
- New LLP Coverage Rule Aimed to Transform Industry Rather Than Eke Out Savings: LDP Social Security Chief
January 15, 2024
- MHLW Issues Notification on Pediatric Development Plans
January 15, 2024
- Pharma Regulation Panel to Explore Potential Criteria for All-Case PMS Requirement
January 15, 2024
- Nobelpharma’s Hypozincemia Med, Jardiance’s CKD Use Up for PAFSC Review
January 15, 2024
- Japan Designates Noto Peninsula Quake as Severe Disaster
January 12, 2024
- MHLW Study Underway on Lab Monkey Shortage, Research Team Frets Dependence on Specific Sources
January 11, 2024
- MHLW Orders Label Revisions for Keytruda, Tecentriq, and More
January 11, 2024
- Handling of Big-Seller Candidates Is Top Priority as Japan Seeks Good Budget Balance: Minister
January 10, 2024
- Drugs Being Delivered to Quake-Hit Areas Day after Request: Minister
January 10, 2024
- Panels Urge OTC Switches “within 3 Years” for Drugs Sold Over the Counter in 2 or More Other Countries
January 5, 2024
- MHLW Unveils Draft Guidelines on Access to Intractable, Pediatric Disease Databases
January 5, 2024
- FY2024 Reform Heralds Shift to Funding Cycle within Drug Budget: MHLW Pharma Director
December 28, 2023
- Japan Sets Up New Pharma Forum to Fight Drug Lag/Loss, Aims to Reflect Proposals in Honebuto
December 28, 2023
- Payers Reiterate Their Push for “1/2” LLP Copay Scenario for Price Gap from Generics
December 28, 2023
- Chuikyo Officially OKs Application of Elective Care for Off-Patent Branded Drugs
December 28, 2023
- Japan Maps Out Fresh 10-Year Strategy for Cancer Research
December 28, 2023
- Regulatory Panel Members Want Clearer Standard for SaMD Efficacy in 2-Stage Approval Scheme
December 27, 2023
- Health Minister Vows to Beef Up Japan’s Innovation Ecosystem in 2024
December 27, 2023
- Health Ministry Panel Explores Vision for Generic Industry, Eyes Structural Reform in 5 Years
December 26, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…